ArticleDiabetologia2025
Insulin resistance in type 1 diabetes is a key modulator of platelet hyperreactivity.
Article in Diabetologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Article
- Systemic metabolic dysfunction drives platelet-mediated inflammation, fibrogenesis, and hepatocarcinogenesis in metabolic dysfunction-associated steatotic liver disease.Clinical and molecular hepatology · 2026Review
- Platelet Indices and Adipokines in Adults with Long-Standing Type 1 Diabetes.Journal of clinical medicine · 2026Article
- An overview of the role of platelets in vascular disease associated with diabetes mellitus.Hormones (Athens, Greece) · 2026Review
- Anthropometry-adjusted TyG indices improve insulin resistance estimation: an exploratory euglycemic-hyperinsulinemic clamp study in Japanese adults without diabetes.Diabetology international · 2026Article
- Insulin Resistance and Platelet Hyperactivity: Hematological Insights and Nutritional Strategies for Vascular Protection.Nutrients · 2026Review
- TyG index predicts adverse cardiovascular outcomes in patients with multimorbidity of hypertension and obstructive coronary artery disease: a cohort study.Frontiers in cardiovascular medicine · 2026Article
- Stratified assessment of platelets in sepsis: from dynamic counts to functional phenotypes.Frontiers in immunology · 2026Review
- The Central Role of Lipid Metabolism Disorders in Diabetes Mellitus: Mechanisms, Clinical Manifestations, and Emerging Therapeutic Strategies.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Review
- P-Selectin and Platelet-Monocyte Interaction in Inflammation: Mechanisms, Hypothesis, and Open Questions.Journal of inflammation research · 2026Review
- The relationship between estimated glucose disposal rate and sarcopenia among middle-aged and older adults.Scientific reports · 2025Article
- Resveratrol as a Potential Platelet Inhibitor in Aspirin-Resistant Diabetic Patients-A Novel Therapeutic Strategy Targeting FLife (Basel, Switzerland) · 2025Review
- Association between estimated glucose disposal rate and the risk of atherosclerotic cardiovascular disease: insight from cross-sectional and retrospective cohort studies.Frontiers in nutrition · 2025Article
- Autologous Blood Clot Therapy for Wounds: Investigating the Chemotactic Effect on PBMCs and Fibroblasts in Diabetes.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair SocietyArticle
- The Triglyceride-glucose Index Predicts Short-Term Mortality in Critically Ill Patients With Cancer-Associated Thrombosis: A Retrospective Cohort Study.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
aims/hypothesisIndividuals with type 1 diabetes are at increased cardiovascular risk, particularly in the presence of insulin resistance. A prothrombotic environment is believed to contribute to this risk but thrombotic pathways in type 1 diabetes are only partially understood and the role of platelets is incompletely studied. We hypothesised that platelets from individuals with type 1 diabetes exhibit platelet hyperactivity due to both increased propensity for activation and diminished sensitivity to inhibition, with an amplified maladaptive phenotype in those with insulin resistance.
methodsBlood samples were obtained from individuals with type 1 diabetes enrolled on the 'Double diabEtes and adVErse cLinical Outcome: identification of mechanistic Pathways' (DEVELOP) study with insulin resistance assessed as estimated glucose disposal rate (eGDR), whereby eGDR >8 or <6 mg kg
resultsA total of 32 individuals with type 1 diabetes were studied (median age [range] of 24 [18-34] years, 59% male, diabetes duration [mean ± SD] of 14.0 ± 6.3 years and HbA CONCLUSIONS/
interpretationOur novel characterisation of platelets in type 1 diabetes shows a maladaptive phenotype with increased basal activity together with hyperactivation following stimulation and diminished responses to inhibition. Insulin resistance appears to further drive this adverse thrombotic phenotype, suggesting an enhanced platelet-driven cardiovascular risk in those with type 1 diabetes and reduced insulin sensitivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.